US · CPRX · BIOTECHNOLOGY
Catalyst Pharmaceuticals, Inc. (CPRX) intrinsic value and stock valuation
$31.49as of 2026-07-21 · Mkt cap 3.83B
Data updated · price as of 2026-07-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Catalyst Pharmaceuticals, Inc. DCF and intrinsic value
InvestorsCraft values CPRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from CPRX’s statements →
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Scholar Rock Holding Corporation (SRRK) $49.82
- Cidara Therapeutics, Inc. (CDTX) $221.38
- Apellis Pharmaceuticals, Inc. (APLS) $41.03
- Kiniksa Pharmaceuticals, Ltd. (KNSA) $50.84
- Beam Therapeutics Inc. (BEAM) $32.80
- IDEAYA Biosciences, Inc. (IDYA) $29.34
- Adaptive Biotechnologies Corporation (ADPT) $15.19
- Mineralys Therapeutics, Inc. (MLYS) $31.54
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
- CEO
- Richard John Daly
- Employees
- 181
- Beta
- 0.72
Explore
Frequently asked questions
What is the intrinsic value of Catalyst Pharmaceuticals, Inc. (CPRX)?
InvestorsCraft does not currently publish an intrinsic value for CPRX. How the IC value is calculated.
Is CPRX undervalued?
InvestorsCraft does not publish an undervaluation signal for CPRX at this time.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Aug 15, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.